Alligator Bioscience Announces Continued Encouraging Overall Survival Benefit for Mitazalimab
Results show a 24-month survival rate of 29.4% for mitazalimab in combination with mFOLFIRINOX, triple that of chemotherapy alone Topline da ...
Notice of extraordinary general meeting in Alligator Bioscience AB
The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedis ...
The Board of Directors of Alligator Bioscience propose a reverse share split of ordinary shares
The Board of Directors of Alligator Bioscience AB (“Alligator Bioscience” or the ”Company”) proposes that an Extraor ...
Alligator Bioscience’s rights issue is registered – conversion of BTU into shares and warrants
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...
Alligator Bioscience carries out a directed issue of units to guarantors and a directed issue of warrants to Fenja Capital in connection with the completed rights issue
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...
Alligator Bioscience announces final outcome in rights issue
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...
Alligator Bioscience announces preliminary outcome in rights issue
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...
Alligator Bioscience Successfully Completes End of Phase 2 Interaction with FDA For Mitazalimab
FDA feedback validates the clinical development strategy and Phase 3 design FDA feedback confirms that the toxicology package is adequate fo ...
Alligator Bioscience Announces Publication of Clinical Data for ATOR-1017 (evunzekibart) in the Journal for ImmunoTherapy of Cancer
Publication validates encouraging clinical safety and tolerability in this first-in-human trial Data show early signs of clinical efficacy i ...